developing new tools for diagnostics Join forces with IMGM Laboratories to make your mirna project a success

Similar documents
microrna Presented for: Presented by: Date:

MicroRNA expression profiling and functional analysis in prostate cancer. Marco Folini s.c. Ricerca Traslazionale DOSL

Benchmark study: Exiqon mircury LNA microrna arrays vs. Supplier A s DNA based capture probes. Includes comparison of:

Patnaik SK, et al. MicroRNAs to accurately histotype NSCLC biopsies

Profiles of gene expression & diagnosis/prognosis of cancer. MCs in Advanced Genetics Ainoa Planas Riverola

micrornas (mirna) and Biomarkers

Corporate Medical Policy

A novel and universal method for microrna RT-qPCR data normalization

Non-Profit Startup Paradigm Launches Cancer Panel Based on DNA, RNA Sequencing

From reference genes to global mean normalization

Screening for novel oncology biomarker panels using both DNA and protein microarrays. John Anson, PhD VP Biomarker Discovery

Evolution of Pathology

Extracellular Vesicle RNA isolation Kits

Products for cfdna and mirna isolation. Subhead Circulating Cover nucleic acids from plasma

MEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site

Inferring condition-specific mirna activity from matched mirna and mrna expression data

QIAGEN's Growing Immuno-Oncology Testing Portfolio

On the Reproducibility of TCGA Ovarian Cancer MicroRNA Profiles

Patient Stratification and Precision Medicine in Pancreatic Cancer

Serum mirna expression profile as a prognostic biomarker of stage II/III

Cellecta Overview. Started Operations in 2007 Headquarters: Mountain View, CA

RECENT ADVANCES IN THE MOLECULAR DIAGNOSIS OF BREAST CANCER

Deploying the full transcriptome using RNA sequencing. Jo Vandesompele, CSO and co-founder The Non-Coding Genome May 12, 2016, Leuven

SUPPLEMENTAY FIGURES AND TABLES

The Cancer Genome Atlas

ExpressArt FFPE Clear RNAready kit

microrna PCR System (Exiqon), following the manufacturer s instructions. In brief, 10ng of

SUPPLEMENTARY INFORMATION

QIAGEN Complete Solutions for Liquid Biopsy Molecular Testing

a) List of KMTs targeted in the shrna screen. The official symbol, KMT designation,

NGS Gateway Lab Services

National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant

Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis

MicroRNA and Male Infertility: A Potential for Diagnosis

Service and Collaboration

The clinical relevance of circulating, cell-free and exosomal micrornas as biomarkers for gynecological tumors

ncounter Assay Automated Process Immobilize and align reporter for image collecting and barcode counting ncounter Prep Station

microrna-200b and microrna-200c promote colorectal cancer cell proliferation via

ARTICLE IN PRESS. Critical Reviews in Oncology/Hematology xxx (2010) xxx xxx

Analysis of small RNAs from Drosophila Schneider cells using the Small RNA assay on the Agilent 2100 bioanalyzer. Application Note

EPIGENOMICS PROFILING SERVICES

microrna analysis for the detection of autologous blood transfusion in doping control

Molecular Testing in Lung Cancer

Profiling of microrna in oral cancer cells identifying mir-10b functions in oncogenesis

HALLA KABAT * Outreach Program, mircore, 2929 Plymouth Rd. Ann Arbor, MI 48105, USA LEO TUNKLE *

ncounter Assay Automated Process Capture & Reporter Probes Bind reporter to surface Remove excess reporters Hybridize CodeSet to RNA

ncounter TM Analysis System

W J C O. World Journal of Clinical Oncology. MicroRNAs as lung cancer biomarkers. Abstract INTRODUCTION TOPIC HIGHLIGHT

Lombardi Cancer Center Georgetown University Washington, DC

RNA preparation from extracted paraffin cores:

Non-Invasive Array Based Screening for Cancer. Dr. Amit Kumar President and CEO CombiMatrix Corporation

numares at a glance company overview 2014 Discover, understand and use biological systems high level NMR analytics

Supplementary materials and methods.

MicroRNAs: a new source of biomarkers in radiation response. Simone Moertl, Helmholtz Centre Munich

About OMICS Group Conferences

Session 4 Rebecca Poulos

microrna Therapeutics Heading Towards the Clinic

Supplementary Online Content

Assaying micrornas in biofluids for detection of drug induced cardiac injury. HESI Annual Meeting State of the Science Session June 8, 2011

Profiles of gene expression & diagnosis/prognosis of cancer Lorena Roa de la Cruz

Assessment of Breast Cancer with Borderline HER2 Status Using MIP Microarray

A two-microrna signature in urinary exosomes for diagnosis of prostate cancer

Study Finds Lung Cancer Subtype Test from UNC, Startup GeneCentric to be Accurate, Reproducible

Integrated platform for liquid biopsy-based personalized cancer medicine

Human diagnostics. Better be Sure: Quantify HDV & HBV viral load. RoboGene product family

Importancia del patólogo en los tumores de origen desconocido

Bootstrapped Integrative Hypothesis Test, COPD-Lung Cancer Differentiation, and Joint mirnas Biomarkers

FAQs for UK Pathology Departments

Simple, rapid, and reliable RNA sequencing

Small RNA-Seq and profiling

STAT1 regulates microrna transcription in interferon γ stimulated HeLa cells

Personalized Therapy for Prostate Cancer due to Genetic Testings

Role of deregulated micrornas in non small cell lung cancer progression using fresh frozen and formalin fixed, paraffin embedded samples

Comparison of Triple Negative Breast Cancer between Asian and Western Data Sets

microrna-guided diagnostics for neuroendocrine tumors

High AU content: a signature of upregulated mirna in cardiac diseases

Disruptive innovation in molecular diagnostics. Hilde Windels CEO Biocartis 25 March 2017

Welcome. Nanostring Immuno-Oncology Summit. September 21st, FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.

MARCH 2017 RESEARCH REPORT

IPA Advanced Training Course

Table S2. Expression of PRMT7 in clinical breast carcinoma samples

Session 4 Rebecca Poulos

Electronic Supplementary Information. Direct chemiluminescence detection of circulating. micrornas in serum samples using a single-strand specific

RASA: Robust Alternative Splicing Analysis for Human Transcriptome Arrays

Outline. Outline. Phillip G. Febbo, MD. Genomic Approaches to Outcome Prediction in Prostate Cancer

Original Article High serum mir-203 predicts the poor prognosis in patients with pancreatic cancer

microrna analysis Merete Molton Worren Ståle Nygård

Paternal exposure and effects on microrna and mrna expression in developing embryo. Department of Chemical and Radiation Nur Duale

ExoQuick Exosome Isolation and RNA Purification Kits

Perfiles de expresión génica y nuevas dianas terapéuticas en cáncer de endometrio

In Situ Hybridization: Market Strategies and Forecasts, US,

Biopharma and HTG Molecular Diagnostics Sample Sensitivity Data

MicroRNAs: novel regulators in skin research

Clinical significance of serum mir-21 in breast cancer compared with CA153 and CEA

MicroRNAs: the primary cause or a determinant of progression in leukemia?

Quality in Control. ROS1 Analyte Control. Product Codes: HCL022, HCL023 and HCL024

Age and sex differences in kidney microrna expression during the life span of F344 rats

A single nucleotide polymorphism in the promoter region of let-7 family is associated with lung cancer risk in Chinese

Identification of a MicroRNA Panel for Clear-cell Kidney Cancer

CUP: Treatment by molecular profiling

Transcription:

micrornas developing new tools for diagnostics Join forces with IMGM Laboratories to make your mirna project a success Dr. Carola Wagner IMGM Laboratories GmbH Martinsried, Germany qpcr 2009 Symposium March 10 th, 2009 Agenda IMGM - your outsourcing partner (in brief) Our service portfolio (in brief) mirna in diagnostics workflow: microarray-based mirna profiling Summary 10.03.2009 IMGM Laboratories 2009 Slide 2

IMGM Laboratories your outsourcing partner 10.03.2009 IMGM Laboratories 2009 Slide 3 IMGM your outsourcing partner some basic facts IMGM Laboratories was founded d in 2001 We are located on the biotech campus Martinsried / Munich We operate as service provider offering advanced genomic services Our customers come from academia, pharma and biotech a flexible and reliable partnership (e.g. small and dedicated team) 10.03.2009 IMGM Laboratories 2009 Slide 4

IMGM your outsourcing partner some basic facts strategic partnership with the Center for human genetics and laboratory medicine Dr. Klein & Dr. Rost full accreditation according to DIN EN ISO/IEC 17025 full accreditation for expression analysis based on whole genome microarrays and quantitative real-time PCR Agilent Certified Service Provider 10.03.2009 IMGM Laboratories 2009 Slide 5 IMGM Laboratories Service Portfolio 10.03.2009 IMGM Laboratories 2009 Slide 6

Service Portfolio 10.03.2009 IMGM Laboratories 2009 Slide 7 Service Portfolio RNA services RNA services: Microarrays (Agilent platform, multiple options) Real-Time PCR (AB 7900HT, TaqMan arrays, 96- and 384-well blocks, gene expression studies) microrna profiling RNA isolation RNA quality control (Agilent Bioanalyzer Nanodrop) 10.03.2009 IMGM Laboratories 2009 Slide 8

micrornas and their potential in diagnostics 10.03.2009 IMGM Laboratories 2009 Slide 9 mirnas in diagnostics mirnas / mirna profiles: association to ~70 diseases (HMDD, human microrna disease database, last update 2008-10-17) active players in human oncogenesis e.g. mir-21 onco-mirna for breast cancer (Qian et al. (2008) Breast Cancer Res Treat; c.f. Sassen et al. (2008) Virchows Arch 452:1-10 10 classify human cancers e.g. Lu et al. (2005) Nature 435:834-838 Volinia et al. (2006) Proc Natl Acad Sci USA 103:2257-2261 10.03.2009 IMGM Laboratories 2009 Slide 10

mirnas in diagnostics mirnas / mirna profiles associated with: disease prognosis: mir-221/222 cluster associated with poor prognostic in thyroid papillary carcinomas, pancreatic adenocarcinoma & glioblastoma (Lesage et al. (2007) Cell Cycle 6) Low let-7(a) expression associated with shorter survival and poor prognosis for lung cancer patients t (Takamizawa et al. (2004)Cancer Res 64:3753-3756; Yanaihara et al. (2006) Cancer Cell 9:189-198) prognosis of therapy outcome and response high expression of mir-21 associated with poor survival and poor therapeutic outcome of colon adenocarcinoma (Schetter et al. (2008) JAMA 299(4):425-436) prediction of chemotherapeutic response in patients with breast cancer according to mirna signature (Salter et al. 2008) PLoSOne 3(4):e1908) 10.03.2009 IMGM Laboratories 2009 Slide 11 mirnas in diagnostics Actual examples of mirna diagnostic tests: Chronic pancreatitis vs. pancreatic cancer (Asuragen) Prediction of colon cancer (launch early 2009, Exiqon A/S) Differentiation of mesothelioma from other cancers (mirview meso, Rosetta Genomics) Identification of squamous-type lung cancers (mirview squam, Rosetta Genomics) Identification of tissue-of-origin of metastatic tumors (mirview mets, Rosetta Genomics) 10.03.2009 IMGM Laboratories 2009 Slide 12

Possibilities for you to join the field of mirna research!!! 10.03.2009 IMGM Laboratories 2009 Slide 13 mirna profiling the general workflow Sample Size IMGM /Customer Agilent Bioanalyzer Catalog/Custom Arrays Project Consulting Sample Preparation Quality Control Agilent DNA Microarrays Functional analysis mirna mimic or inhibition Hit Validation with qpcr Bioinformatic Data Analysis Customer AB7900HT/TLDAs e.g. mrna microarrays (GEx) 10.03.2009 IMGM Laboratories 2009 Deregulated Genes Slide 14

mirna profiling sample preparation Sample types: Cells Tissues Blood and PBMCs FFPE e.g. Li et al. (2007) BMC Biotechnology 7:36 Xi et al. (2007) RNA 13:1668-1674 Siebolts et al. (2009) J Clinc Path 62(1):84-88 Body fluids e.g. serum, urine, salvia, amniotic fluid, pleural fluid e.g. Chen et al. (2008) Cell Research 18:997-1006 Gilad et al. (2008) PLoS One 3 (9):3148 Hunter et al. (2008) PLoS One 3 (11):e3694 10.03.2009 IMGM Laboratories 2009 Slide 15 mirna profiling (mi)rna quality control & quantification www.agilent.com/chem/labonchip 10.03.2009 IMGM Laboratories 2009 Slide 16

Tissot (2008) Agilent Application Note, Publication Number 5989-7878EN; www.agilent.com/chem/laponchip 10.03.2009 IMGM Laboratories 2009 Slide 17 mirna profiling e.g. Agilent Microarray Workflow Total RNA incl. small RNAs (100ng) Labeled RNAs direct RNA 3 end Labeling with Cy3-pCp hybridization on microarrays mirna profile 10.03.2009 IMGM Laboratories 2009 Slide 18

mirna profiling Data analysis Technical Note 15 (3), www.ambion.com 10.03.2009 Yanaihara et al. (2006) Cancer Cell 9(3):189-198 IMGM Laboratories 2009 Slide 19 mirna profiling Sample treated log2 data Data analysis Collaborative work with SIRION BIOTECH: Thirion et al. (2009) qpcr 2009 RNAi: microrna sirna applications SSample_untreated l d log2 data 10.03.2009 IMGM Laboratories 2009 Slide 20

mirna profiling Hit validation by qpcr linear Fold Change 6 4 * ** * ** 2-2 2 0 2 calibrator mir 103 calibrator mir 27a calibrator mir 23b + mir_103 4 Collaborative work with SIRION BIOTECH: Thirion et al. (2009) qpcr 2009 RNAi: 66 microrna sirna applications 8 10 * p<0.05 ** p<0.01 10.03.2009 IMGM Laboratories 2009 Slide 21 mirna profiling e.g. functional analysis by mrna expression profiling mirna overexpression mirna inhibition mrna profiling = gene expression analysis www.thco.com.tw 10.03.2009 IMGM Laboratories 2009 Slide 22

Summary Single mirnas / mirna profiles in relation to diagnostics: Well established mirna technologies Increased number of publications with promising results First diagnostic tests t launched mirna research for you powered by IMGM laboratories: Advanced genomic services with one focus on RNA services and mirna services State-of-the-art technology to provide top-quality data Full accreditation especially for microarray- and qpcr-based expression analysis Sound bioinformatics to extract meaningful results Expert knowledge in molecular genetics and medical diagnostics 10.03.2009 IMGM Laboratories 2009 Slide 23 Thank you very much for your attention! We are open for business The IMGM Laboratories Team D. Wiegand, M. Hirt, S. Brauer, S. Kotschote, H-G. Klein, R. Oehlmann, C. Wagner, M. Sohns www.imgm.com 10.03.2009 IMGM Laboratories 2009 Slide 24